Idecabtagene vicleucel (ide-cel)
Treatment for Multiple Myeloma
Typical Dosage: Single intravenous infusion of 150-450 × 10^6 CAR-positive T cells
Effectiveness
95%
Safety Score
20%
Clinical Trials
28
Participants
1K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Single intravenous infusion of 150-450 × 10^6 CAR-positive T cells
Time to Effect
1-3 months
Treatment Duration
One-time infusion, followed by long-term monitoring
Evidence Quality
MODERATEConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$419,500
Monitoring:$50,000
Side Effect Mgmt:$70,000
Total Annual:$539,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$475,000/QALY
QALYs Gained
1.25
Outcome-Based Costs
Cost per Responder
$674,375
Cost per Remission
$1,348,750
Comparison vs Standard of Care (SOC) for triple-class refractory MM
Cost Difference
+$450,000/year
More expensive
QALY Difference
+1.25 QALYs
Better outcomes
Dominance
No dominance
Idecabtagene vicleucel (ide-cel) Outcomes
for Multiple Myeloma
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+80%
Remission Rate
+40%
Common Side Effects
Cytokine Release Syndrome (CRS)
+85%
Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)
+30%
Myelosuppression (prolonged)
+85%
Infections
+40%
Hypogammaglobulinemia
+50%
Active Clinical Trials
12 active trials recruiting for Idecabtagene vicleucel (ide-cel) in Multiple Myeloma
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
NCT06698887RECRUITING
15 participants
OBSERVATIONAL
Hwasun, South Korea +4 more
Started: Sep 11, 2024
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
NCT06154902ACTIVE NOT RECRUITING
350 participants
OBSERVATIONAL
Paris, France
Started: Jul 29, 2022
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
NCT05393804RECRUITINGPHASE2
32 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: May 20, 2022
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806ACTIVE NOT RECRUITINGPHASE3
618 participants
INTERVENTIONAL
Los Angeles, United States +100 more
Started: Oct 16, 2023
The Norwegian Immunotherapy in Multiple Myeloma Study
NCT06855121RECRUITING
400 participants
OBSERVATIONAL
Arendal, Norway +22 more
Started: Jan 15, 2025
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06357754RECRUITING
50 participants
OBSERVATIONAL
Portland, United States +7 more
Started: Oct 6, 2023
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Charlotte, United States +1 more
Started: Feb 28, 2025
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551RECRUITINGPHASE1, PHASE2
49 participants
INTERVENTIONAL
Boston, United States +2 more
Started: Nov 1, 2024
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
NCT06048250RECRUITINGPHASE1
15 participants
INTERVENTIONAL
Duarte, United States
Started: Apr 9, 2024
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888RECRUITINGPHASE2
78 participants
INTERVENTIONAL
Irvine, United States +72 more
Started: Aug 27, 2024
Elranatamab in R/R Multiple Myeloma
NCT06138275RECRUITINGPHASE2
32 participants
INTERVENTIONAL
Boston, United States +2 more
Started: Mar 8, 2024
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078ACTIVE NOT RECRUITINGPHASE2
248 participants
INTERVENTIONAL
Scottsdale, United States +24 more
Started: Dec 13, 2018
Completed Clinical Trials
5 completed trials for Idecabtagene vicleucel (ide-cel) in Multiple Myeloma
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
NCT04196491COMPLETEDPHASE1
13 participants
INTERVENTIONAL
Phoenix, United States +21 more
Started: May 27, 2020
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
NCT05032820COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Duarte, United States +14 more
Started: Jan 5, 2022
Study of bb2121 in Multiple Myeloma
NCT02658929COMPLETEDPHASE1
67 participants
INTERVENTIONAL
Stanford, United States +8 more
Started: Dec 22, 2015
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748COMPLETEDPHASE2
149 participants
INTERVENTIONAL
San Francisco, United States +47 more
Started: Dec 13, 2017
Study of bb21217 in Multiple Myeloma
NCT03274219COMPLETEDPHASE1
72 participants
INTERVENTIONAL
San Francisco, United States +10 more
Started: Aug 16, 2017
Showing 20 of 28 total trials